PDCD1 and cancer: Currently, some of the ICIs including the anti-CTLA-4 agent, ipilimumab, Tremelimumab; anti-PD-1 agents, nivolumab and pembrolizumab; and anti-PDL-1 agent, Atezolizumab, Avelumab, Cemiplimab, Durvalumab, ipilimumab, and atezolizumab [121,122,123] have been approved for the treatment of certain types of cancer [124].